Stay updated on Pembrolizumab for Leptomeningeal Disease Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Leptomeningeal Disease Clinical Trial page.

Latest updates to the Pembrolizumab for Leptomeningeal Disease Clinical Trial page
- CheckyesterdayChange DetectedThe page now shows Revision: v3.6.5 and a set of legacy study-record details has been removed, effectively streamlining the page content while preserving the main study information.SummaryDifference16%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page now displays a new revision label Revision: v3.6.4, and the previous Revision: v3.6.3 label has been removed. This indicates a small internal update to the page versioning, not changes to the study details or user-facing content.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedThe page now shows Revision: v3.6.3, indicating a small deployment update.SummaryDifference0.1%

- Check44 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a newer version of the page; the previous revision tag was removed to reflect the update.SummaryDifference0.1%

- Check58 days agoChange DetectedNew navigation/help sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment status message 'No longer looking for participants' now appears on the page. The label for Intervention/Treatment was standardized, and the revision tag was updated from v3.5.5 to v3.6.0.SummaryDifference0.6%

- Check65 days agoChange DetectedThe ClinicalTrials.gov entry version was updated from v3.5.4 to v3.5.5, indicating a new revision of the study record. This reflects a version update, typically for minor edits or corrections, not a change to study design or outcomes.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Leptomeningeal Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Leptomeningeal Disease Clinical Trial page.